Eversense 365 CGM Outperforms Competitors in Real Clinical Data

Researchers tested Eversense 365 head-to-head against other glucose monitors that people with diabetes actually use every day. The results were clear: the implanted sensor kept blood sugar levels more stable over a full year compared to patch-based competitors. Why does a one-year lifespan matter? It cuts down on the constant swapping and reinsertion that burns out patients, plus it means fewer trips to the clinic and less disruption to daily life.

What caught attention at the ADA presentation was that Eversense held its own in both scenarios—whether people used it standalone or paired it with an insulin pump running automated algorithms. That's harder than it sounds because closed loop systems are sensitive devices that need rock-solid sensor data. The company proved its technology works reliably in both camps, which expands its appeal beyond one narrow use case.

The clinical evidence matters because CGM makers live and die by real-world performance data. Patients see these numbers. Insurers see these numbers. Doctors decide coverage based on this stuff. Eversense just handed them a solid case for why implanting a sensor once a year beats replacing patches every two weeks.